Bayer (ETR:BAYN) stock price target increased to 124.00EUR, issued a research note today by Deutsche Bank AG
- Updated: October 17, 2016
In a report released on 10/18/2016 Deutsche Bank AG increased the stock price target of Bayer (ETR:BAYN) to 124.00EUR indicating a possible upside of 0.39%.
Previously on 10/17/2016, Deutsche Bank AG reported on Bayer (ETR:BAYN) increased the target price from 0.00EUR to 124.00EUR. At the time, this indicated a possible upside of 0.39%.
Yesterday Bayer (ETR:BAYN) traded 0.00% even at 89.42EUR. The company’s 50-day moving average is 0.04EUR and its 200-day moving average is 0.03EUR. The last closing price is up -9.38% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 1,350 shares of the stock traded hands, up from an average trading volume of 211
See Chart Below
With a total market value of 0 EUR, Bayer has with a one year low of 0.01EUR and a one year high of 0.08EUR .
More About Bayer (ETR:BAYN)
Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, adhesives and sealants; and selected chemical intermediates.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.